Results published for Venclexta + Gazyva for CLL

Create PDF

July 2019—Genentech announced results from the pivotal phase three CLL14 study in previously untreated chronic lymphocytic leukemia showing that Venclexta (venetoclax) plus Gazyva (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival. The 12-month, fixed-duration, chemotherapy-free combination reduced the risk of disease worsening or death by 65 percent compared with Gazyva plus chlorambucil (PFS, as assessed by investigator; hazard ratio, 0.35; 95 percent CI, 0.23–0.53; P < 0.001) when given to people with previously untreated CLL who have coexisting medical conditions. The results were presented at the 2019 American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine (Fisher K, et al. 380:2225–2236).